This year we celebrate the tenth anniversary of Global Accessibility Awareness Day (GAAD), and we look back on the development of our own accessible website a year ago.
The clinical trial named Brighten evaluates the safety and tolerability of investigational RNA therapy sepofarsen in children with Leber congenital amaurosis.
A blog by Martin Hills from Retina UK living with Retinitis Pigmentosa on why research participation and genetic testing are essential in for drug development and how to get involved.
In a Phase 1/2 clinical trial investigational RNA therapy QR-421a showed a benefit in vision. ProQR plans to start final phase trials for USH2A mediated retinitis pigmentosa.
